PURPOSE: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze (18)F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS). METHODS: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were co-registered to FDG positron emission tomography (PET) images. PET data were normalized. Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized). 2D analysis methods were compared. Cox proportional hazards models were used to estimate the association between these methods and PFS. RESULTS: Strongest correlations between 2D and 3D methods were with analyses using postcontrast T1 images for volume of interest (VOI). The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS. CONCLUSIONS: This study of a series of pretreatment AA patients suggests that 3D PET methods using VOIs based on postcontrast T1 correlate with 2D methods and are related to PFS. These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined. Future rigorous multi-institutional protocols with larger numbers of patients will be required for validation.
PURPOSE: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze (18)F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS). METHODS: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were co-registered to FDG positron emission tomography (PET) images. PET data were normalized. Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized). 2D analysis methods were compared. Cox proportional hazards models were used to estimate the association between these methods and PFS. RESULTS: Strongest correlations between 2D and 3D methods were with analyses using postcontrast T1 images for volume of interest (VOI). The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS. CONCLUSIONS: This study of a series of pretreatment AA patients suggests that 3D PET methods using VOIs based on postcontrast T1 correlate with 2D methods and are related to PFS. These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined. Future rigorous multi-institutional protocols with larger numbers of patients will be required for validation.
Authors: O De Witte; M Levivier; P Violon; I Salmon; P Damhaut; D Wikler; J Hildebrand; J Brotchi; S Goldman Journal: Neurosurgery Date: 1996-09 Impact factor: 4.654
Authors: D Delbeke; C Meyerowitz; R L Lapidus; R J Maciunas; M T Jennings; P L Moots; R M Kessler Journal: Radiology Date: 1995-04 Impact factor: 11.105
Authors: G Di Chiro; R L DeLaPaz; R A Brooks; L Sokoloff; P L Kornblith; B H Smith; N J Patronas; C V Kufta; R M Kessler; G S Johnston; R G Manning; A P Wolf Journal: Neurology Date: 1982-12 Impact factor: 9.910
Authors: T Young Poussaint; P C Phillips; S Vajapeyam; F H Fahey; R L Robertson; S Osganian; U Ramamurthy; R V Mulkern; S T Treves; J M Boyett; L E Kun Journal: AJNR Am J Neuroradiol Date: 2007-04 Impact factor: 3.825
Authors: Katherine A Zukotynski; Frederic H Fahey; Sridhar Vajapeyam; Sarah S Ng; Mehmet Kocak; Sridharan Gururangan; Larry E Kun; Tina Y Poussaint Journal: J Nucl Med Date: 2013-06-25 Impact factor: 10.057
Authors: Katherine A Zukotynski; Frederic H Fahey; Mehmet Kocak; Abass Alavi; Terence Z Wong; S Ted Treves; Barry L Shulkin; Daphne A Haas-Kogan; Jeffrey R Geyer; Sridhar Vajapeyam; James M Boyett; Larry E Kun; Tina Young Poussaint Journal: J Nucl Med Date: 2011-01-13 Impact factor: 10.057
Authors: Katherine A Zukotynski; Sridhar Vajapeyam; Frederic H Fahey; Mehmet Kocak; Douglas Brown; Kelsey I Ricci; Arzu Onar-Thomas; Maryam Fouladi; Tina Young Poussaint Journal: J Nucl Med Date: 2017-03-30 Impact factor: 10.057
Authors: Virginie Frings; Adrianus J de Langen; Maqsood Yaqub; Robert C Schuit; Astrid A M van der Veldt; Otto S Hoekstra; Egbert F Smit; Ronald Boellaard Journal: Mol Imaging Biol Date: 2014-02 Impact factor: 3.488
Authors: Katherine Zukotynski; Frederic Fahey; Mehmet Kocak; Larry Kun; James Boyett; Maryam Fouladi; Sridhar Vajapeyam; Ted Treves; Tina Y Poussaint Journal: J Nucl Med Date: 2014-07-28 Impact factor: 10.057
Authors: Reza Vali; Adam Alessio; Rene Balza; Lise Borgwardt; Zvi Bar-Sever; Michael Czachowski; Nina Jehanno; Lars Kurch; Neeta Pandit-Taskar; Marguerite Parisi; Arnoldo Piccardo; Victor Seghers; Barry L Shulkin; Pietro Zucchetta; Ruth Lim Journal: J Nucl Med Date: 2021-01 Impact factor: 11.082